Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10161685
• 负责人: Oscar L. Lopez
• 金额: $ 305.25万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10161685
• 关键词: Address; Adult; Advocacy; Altruism; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Area; Awareness; Basic Science; Behavioral Symptoms; Biological; Biological Markers; Biology; Blood; Brain; Caregivers; Caring; Clinic; Clinical; Clinical Course of Disease; Clinical Data; Clinical Research; Clinical assessments; Cognition; Cognition Disorders; Cognitive; Collaborations; Communication; Communities; Data; Data Collection; Databases; Dementia; Development; Early Diagnosis; Early treatment; Environment; Etiology; Evaluation; Evolution; Faculty; Family; Foundations; Functional disorder; Funding; Genetic; Goals; Grant; Healthcare; Heterogeneity; Human Resources; Image; Imaging technology; Individual; Infrastructure; Institution; International; Investments; Lead; Leadership; MRI Scans; Methodology; Methods; Motivation; Natural History; Nerve Degeneration; Neurobehavioral Manifestations; Outcome; Participant; Pathogenesis; Pathologic; Pathologic Processes; Patient Care; Patients; Pharmaceutical Preparations; Physicians; Positron-Emission Tomography; Process; Protocols documentation; Psychoses; Public Health; Research; Research Personnel; Research Training; Risk Factors; Role; Sampling; Scientist; Solid; Standardization; Students; Symptoms; Testing; Tracer; Training; Training Programs; Training and Education; Universities; Validation; base; career; clinical biomarkers; cohort; data management; design; disease phenotype; education research; effective therapy; efficacious treatment; genetic risk factor; health care delivery; improved; innovation; insight; interdisciplinary approach; international center; member; mild cognitive impairment; multidisciplinary; neurogenetics; neuroimaging; neuropathology; neuropsychiatry; novel; novel therapeutics; outreach; outreach program; programs; recruit; research study

Overall: Summary/Abstract: The University of Pittsburgh Alzheimer’s Disease Research Center (PITT- ADRC) has shown a clear scientific evolution over the past three decades. Since our inception, we have advanced the areas of AD neuropsychiatry, genetics, natural history of AD, validation of clinical criteria, and clinico-pathological correlations, and have pioneered the development of PET amyloid tracers, which have transformed AD research. We have used a multidisciplinary approach to better understand the transition from normal cognition to dementia, have explored the biology of more aggressive forms of AD characterized by psychosis, and have made and contributed to new insights in genetics. This solid scientific background and investment in junior investigators has allowed the PITT-ADRC to develop areas of excellence, which form the foundation of our Center going forward. These are reflected in the Center’s cores, and most notably in the large number of studies we support in these areas in Pittsburgh and at national and international level. The PITT-ADRC is committed to remain at the forefront of the scientific efforts to understand the pathological processes involved in the etiology of AD. Along with the high level of research conducted by the PITT-ADRC, we are also dedicated to developing strong training programs to promote the careers of young investigators, consolidate the career of midlevel investigators, and to create strong ties with the community through educational and support programs. The PITT-ADRC is highly committed to leverage the strengths of the network of Centers to provide large numbers of samples and standardized clinical data collection from our participants. The PITT-ADRC has designed novel methodology that improves the accessibility of its database to local and national researchers, and it has been a key player in multiple studies that advanced the understanding of AD pathology and its possible implications for the development of novel treatments and other symptoms. Therefore, we provide an excellent environment that enhances cutting-edge research by bringing together a multidisciplinary team of investigators to study AD and other dementias, and to improve health care delivery. The methodology proposed in this application will lead us to the creation of a unique and well-characterized cohort of patients and normal control subjects assessed with state of the art clinical and biomarker methods. This will allow us to test multiple scientific hypotheses and to examine the short- and long-term public health outcomes of the pathophysiology of cognitive disorders in the adult. We believe that the PITT -ADRC will be at the center of the new era of AD research that will require a wealth of clinical and biological data, highly sophisticated biomarker methodologies, close inter-relationship among centers and institutions, creation and optimization of human resources, and enhanced communication with patients and families.

总体：摘要/摘要： 匹兹堡大学阿尔茨海默病研究中心(匹兹堡- ADRC)在过去30年中显示出明显的科学演变。自成立以来，我们一直 推进阿尔茨海默病的神经精神病学、遗传学、阿尔茨海默病的自然病史、临床标准的验证以及 临床病理相关性，并开创了PET淀粉样示踪剂的发展，它已经 改变了AD研究。我们使用了多学科方法来更好地理解从 对痴呆症的正常认知，已经探索了更具侵袭性的AD生物学形式的特点 精神病，并在遗传学方面做出了新的见解并做出了贡献。这个坚实的科学背景和 对初级调查人员的投资使PIT-ADRC能够开发卓越的领域，这些领域形成了 我们中心的基础正在向前迈进。这些都反映在中心的核心中，最引人注目的是 我们在匹兹堡以及国家和国际层面支持这些领域的大量研究。 PIT-ADRC致力于继续站在科学努力的前沿，以了解 阿尔茨海默病的病理过程与病因有关。同时进行的高水平研究由 PIT-ADRC，我们还致力于制定强有力的培训计划，以促进年轻人的职业生涯 调查人员，巩固中层调查人员的职业生涯，并与社区建立牢固的联系 通过教育和支持计划。 PIT-ADRC高度致力于利用中心网络的优势，为 样本数量和标准化临床数据收集自我们的参与者。PIT-ADRC已经 设计了新的方法，改善了其数据库对当地和国家研究人员的可及性， 它在多项研究中发挥了关键作用，这些研究促进了对AD病理及其机制的理解 可能对开发新的治疗方法和其他症状产生影响。因此，我们提供了一个 通过汇聚一个多学科的团队来加强尖端研究的良好环境 调查人员将研究阿尔茨海默病和其他痴呆症，并改善医疗保健服务。 在本申请中提出的方法论将引导我们创建一个独特的、具有良好特征的 用最先进的临床和生物标记物方法评估患者和正常对照组的队列。 这将使我们能够测试多种科学假设，并检查短期和长期的公共健康 成人认知障碍的病理生理学结果。 我们相信，PIT-ADRC将处于AD研究的新时代的中心，这将需要 丰富的临床和生物学数据，高度复杂的生物标志物方法，密切的相互关系 在中心和机构之间，创造和优化人力资源，加强沟通 和病人和家人在一起。